Testosterone and Risk-Taking: 52-Study Analysis Debunks Myth

One of the most durable beliefs about testosterone is that it makes men reckless -- a chemical accelerator for gambling, aggression, and bad decisions. A 2026 meta-analysis pooling 52 studies and 17,340 participants just put that idea to a rigorous test. The result: essentially no link.

The study, published in Neuroscience and Biobehavioral Reviews and led by Irene Sanchez Rodriguez and colleagues, is the largest quantitative synthesis to date of testosterone and risk-taking. Its conclusion matters for anyone weighing testosterone replacement therapy, because the fear that TRT will alter personality or judgment is one of the most common reasons men hesitate to treat a genuine deficiency.

Key Takeaways

• 52 studies, 17,340 participants -- the largest analysis of testosterone and risk-taking to date
• Overall association between testosterone and risk-taking was essentially zero
• A small link appeared only in lottery-style economic tasks, not other measures
• Indirect measures (finger-length ratios) suggested links; rigorous blood and saliva testing did not
• The effect did not differ by sex -- testosterone did not explain male-female differences in risk
• Practical message: the "testosterone makes you reckless" fear is not supported, and should not be a reason to avoid treating real hypogonadism

What the Researchers Did

The team ran a systematic review and meta-analysis -- the highest tier of evidence synthesis, which pools results across many independent studies to find the signal that any single study is too small to confirm.

Study Design

Parameter	Detail
Method	Systematic review and meta-analysis
Studies included	52
Total participants	17,340
Testosterone measures	Blood, saliva, hormone administration, finger-length ratios
Risk measures	Lottery and gambling tasks, impulsive-choice games, self-report questionnaires
Primary question	Is testosterone associated with risk-taking behavior?
Secondary question	Does testosterone explain sex differences in risk-taking?
Journal	Neuroscience and Biobehavioral Reviews, 2026

The breadth of measurement methods is what makes this analysis useful. Earlier individual studies often used a single tool -- one gambling task, or one saliva sample -- and reached conflicting conclusions. By pooling across direct hormone tests, controlled administration experiments, and self-reports, the authors could see which findings held up and which were artifacts of weak methods.

The Finding in Context

The headline is the near-zero overall effect. But the nuance is where the value is.

The Association Was Essentially Zero -- With One Narrow Exception

Across the full dataset, people with higher testosterone were not consistently more willing to gamble, invest, or describe themselves as risk takers. The pooled effect was, in the authors' framing, practically nothing.

A modest positive association appeared in one specific context: studies that used lottery-style economic tasks. Other approaches -- impulsive-choice games, self-report personality questionnaires, and hormone-administration experiments -- showed no significant link. That pattern argues against a general biological effect and in favor of something far more specific: testosterone may nudge behavior on a narrow class of structured economic decisions, not life writ large.

Weak Measures Inflated the Signal

One of the most telling results: indirect measures of testosterone -- such as the ratio between the index and ring finger, a proxy for prenatal hormone exposure -- were more likely to suggest a connection than rigorous direct testing of blood or saliva. Direct hormone measurement and controlled administration, the most reliable approaches, did not.

When the strongest methods find the weakest effect, that is a red flag for a myth. It suggests the "testosterone drives risk" association is partly an artifact of measurement noise rather than a real causal pathway.

It Did Not Explain Sex Differences

The researchers specifically tested whether testosterone accounts for the well-documented tendency of men, on average, to take more risks than women. It did not. The testosterone-risk relationship did not differ significantly by sex, which undercuts the popular evolutionary-psychology story that male risk-taking is a direct downstream effect of higher androgen levels.

What This Means for TRT Patients

The Personality Fear Is Not Supported

A recurring worry among men considering testosterone replacement therapy is that it will change who they are -- making them aggressive, impulsive, or prone to bad decisions. This meta-analysis is the strongest evidence yet that normal variation in testosterone does not work that way, and the studies that directly administered testosterone found no reliable risk effect either.

That aligns with the broader clinical literature. Properly dosed TRT in men with deficiency is not associated with increased aggression. The aggression and recklessness people picture comes from supraphysiological anabolic steroid abuse -- doses many times higher than therapeutic replacement -- which is a fundamentally different exposure.

What TRT Actually Changes

The consistent, well-documented psychological effects of treating genuine low testosterone are not about risk or aggression at all:

1. Mood -- Meta-analyses and randomized trials show reduced depressive symptoms in hypogonadal men, particularly older men and those with clearly low levels.
2. Energy and fatigue -- Reduced fatigue is one of the most reliable improvements, and a major driver of quality-of-life gains.
3. Motivation and drive -- Restoring testosterone to the therapeutic range commonly restores the sense of drive that deficiency erodes.
4. Confidence and well-being -- Improvements in self-confidence and overall well-being are repeatedly reported, tracking the physical and energetic gains.

These are reversals of a deficiency state, not personality engineering. The TRT mental-health timeline covers when these changes typically appear and how to tell genuine improvement from placebo. For a fuller picture of how mood evolves on therapy, see the mental-health response timeline and the broader results timeline.

A Biopsychosocial Framework, Not a Hormone Dial

The authors are explicit that risk-taking reflects "the interaction of task demands, cognitive-affective processes, and situational context, with endocrine effects appearing narrow, context-dependent, and method-specific." In plain terms: how much risk a person takes depends on the situation, their personality, their upbringing, and the emotions of the moment far more than on a single hormone.

This is the opposite of the cartoon model where testosterone is a throttle. It also explains why decades of research produced conflicting results -- studies were measuring a context-dependent behavior and attributing it to a hormone that, on its own, barely moves the needle.

How This Fits the Larger Testosterone Picture

This is not the only recent finding pushing back on simplistic testosterone narratives. The science has been steadily replacing fear-based assumptions with measured, conditional ones:

• The TRAVERSE trial found no increase in major adverse cardiovascular events from TRT, though it flagged real signals for atrial fibrillation and pulmonary embolism.
• A Cambridge genetic study found a modest cardiovascular signal from lifelong genetically high testosterone -- but one mediated largely by blood pressure, not a blanket danger.
• A real-world study of 9,537 men on TRT for a median of 4.2 years reinforced the overall safety of monitored therapy.

The throughline is consistency: testosterone is neither a miracle nor a menace. Its effects are specific, dose-dependent, and best understood through evidence rather than reputation. The risk-taking meta-analysis removes one of the oldest and least evidence-based items from the "menace" column.

What You Should Actually Do

If the fear of personality change has been holding you back from addressing symptoms of low testosterone, this study should ease it. The more relevant questions are practical:

1. Confirm you actually have low testosterone -- Symptoms overlap with many conditions. Get proper testing with morning total and free testosterone, ideally repeated.
2. Work with a clinic that monitors the real risks -- Blood pressure, hematocrit, and estradiol are the parameters that matter on TRT, not behavior. A disciplined clinic tracks these by default.
3. Set realistic expectations -- Expect improvements in energy, mood, and motivation if you are genuinely deficient. Do not expect -- or fear -- a new personality.
4. Compare your options -- If you are evaluating where to start, the clinic comparison breaks down monitoring quality, pricing, and physician oversight across providers.

The Bottom Line

The largest analysis ever conducted on testosterone and risk-taking -- 52 studies, 17,340 people -- found essentially no link. The only positive signal appeared in a narrow class of lottery-style economic tasks, and the most rigorous measurement methods found the weakest effects. Testosterone did not explain why men, on average, take more risks than women.

For people considering TRT, the practical implication is liberating: the "testosterone makes you reckless" story is not supported by the pooled evidence. What treating real deficiency reliably does is restore mood, energy, and motivation -- not rewrite judgment or personality. The risks worth monitoring on testosterone therapy are physiological, and they are manageable with a clinic that does the bloodwork. Behavior is not on that list.

References

1. Sanchez Rodriguez I, Bailo L, Panizza F, Ricciardi E, Bossi F. No relationship between testosterone and risk aversion: a meta-analytic review. Neuroscience and Biobehavioral Reviews. 2026. DOI: 10.1016/j.neubiorev.2025.106xxx
2. Lin Y-H, et al. Psychiatric and Cognitive Effects of Testosterone Therapy in Adult Men: A Systematic Review of Clinical Evidence and Mechanistic Insights. Cureus. 2025.
3. Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598-1605. DOI: 10.1111/andr.12867
4. Lincoln GA, et al. TRAVERSE: Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389:107-117.